Perioperative dynamics of siglec-15 and soluble PD-L1 in ovarian cancer surgery: Influence of anaesthetic technique on immune regulation

Cui Zhao, Linqian Zhang, Linqian Zhang, Meng Wang, Meng Wang, Yangtao Gao, Yangtao Gao, Mingjie Chen, Mingjie Chen, Long Qi, Long Qi, Jiayi Fu, Jiayi Fu, Yingui Sun, Yingui Sun, Shuo Feng, Shuo Feng

Abstract

This prospective observational study investigated the perioperative dynamics of circulating sialic acid-binding immunoglobulin-like lectin 15 (SIGLEC-15) and soluble programmed death-ligand 1 (sPD-L1) in patients with ovarian cancer undergoing surgery with either total intravenous anesthesia or inhalational anesthesia. Patients were consecutively enrolled, and peripheral blood samples were collected at predefined perioperative time points. Biomarker levels were measured and compared between anesthesia groups, and their associations with immune and inflammatory parameters were analyzed using appropriate statistical methods. Following surgery, levels of SIGLEC-15 and soluble programmed death-ligand 1 increased significantly, peaking at 24 hours and remaining elevated at 72 hours, with more pronounced changes observed in the inhalational anesthesia group. Elevated biomarker levels were associated with greater immune dysregulation, reflected by alterations in natural killer cell proportion, CD4 to CD8 T-cell ratios, and increased levels of interleukin-6 and cortisol. These findings suggest that SIGLEC-15 and soluble programmed death-ligand 1 may serve as blood-based indicators of perioperative immune status. However, their long-term clinical significance requires further investigation. Overall, this study underscores the importance of dynamic monitoring of immune biomarkers during the surgical period to better understand their role in ovarian cancer management.

Full Text:

PDF

References

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May-Jun;74(3):229-263.

Ng JS, Low JJ, Ilancheran A. Epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2012 Jun;26(3):337-45.

Chen J, Yang L, Ma Y, Zhang Y. Recent advances in understanding the immune microenvironment in ovarian cancer. Front Immunol. 2024 Jun 5;15:1412328.

Wang ZB, Zhang X, Fang C, Liu XT, Liao QJ, Wu N, Wang J. Immunotherapy and the ovarian cancer microenvironment: Exploring potential strategies for enhanced treatment efficacy. Immunology. 2024 Sep;173(1):14-32.

Peng Z, Li M, Li H, Gao Q. PD-1/PD-L1 immune checkpoint blockade in ovarian cancer: Dilemmas and opportunities. Drug Discov Today. 2023 Aug;28(8):103666.

Vallejo R, Hord ED, Barna SA, Santiago-Palma J, Ahmed S. Perioperative immunosuppression in cancer patients. J Environ Pathol Toxicol Oncol. 2003;22(2):139-46.

Sekandarzad MW, van Zundert AAJ, Lirk PB, Doornebal CW, Hollmann MW. Perioperative Anesthesia Care and Tumor Progression. Anesth Analg. 2017 May;124(5):1697-1708.

Murphy O, Forget P, Ma D, Buggy DJ. Tumour excisional surgery, anaesthetic-analgesic techniques, and oncologic outcomes: a narrative review. Br J Anaesth. 2023 Dec;131(6):989-1001.

Bezu L, Akçal Öksüz D, Bell M, Buggy D, Diaz-Cambronero O, Enlund M, Forget P, Gupta A, Hollmann MW, Ionescu D, Kirac I, Ma D, Mokini Z, Piegeler T, Pranzitelli G, Smith L, The EuroPeriscope Group. Perioperative Immunosuppressive Factors during Cancer Surgery: An Updated Review. Cancers (Basel). 2024 Jun 22;16(13):2304.

Tseng WC, Lee MS, Lin YC, Lai HC, Yu MH, Wu KL, Wu ZF. Propofol-Based Total Intravenous Anesthesia is Associated with Better Survival than Desflurane Anesthesia in Epithelial Ovarian Cancer Surgery: A Retrospective Cohort Study. Front Pharmacol. 2021 Sep 24;12:685265.

Shen H, Pang Q, Gao Y, Liu H. Effects of epidural anesthesia on the prognosis of ovarian cancer-a systematic review and meta-analysis. BMC Anesthesiol. 2023 Nov 29;23(1):390.

Koukourakis MI, Kontomanolis E, Sotiropoulou M, Mitrakas A, Dafa E, Pouliliou S, Sivridis E, Giatromanolaki A. Increased Soluble PD-L1 Levels in the Plasma of Patients with Epithelial Ovarian Cancer Correlate with Plasma Levels of miR34a and miR200. Anticancer Res. 2018 Oct;38(10):5739-5745.

Buderath P, Schwich E, Jensen C, Horn PA, Kimmig R, Kasimir-Bauer S, Rebmann V. Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer. Front Oncol. 2019 Oct 15;9:1015.

Chen L, Chao Y, Li W, Wu Z, Wang Q. Soluble immune checkpoint molecules in cancer risk, outcomes prediction, and therapeutic applications. Biomark Res. 2024 Sep 2;12(1):95.

Wang J, Sun J, Liu LN, Flies DB, Nie X, Toki M, Zhang J, Song C, Zarr M, Zhou X, Han X, Archer KA, O'Neill T, Herbst RS, Boto AN, Sanmamed MF, Langermann S, Rimm DL, Chen L. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat Med. 2019 Apr;25(4):656-666.

Zhao A, Hu S, Qiu Y, Zhang P, Xu T. Predicting ovarian cancer prognosis and immunotherapy response through siglec15 and PD-L1 expression analysis. Transl Oncol. 2025 Dec;62:102563.

Kurosawa S. Anesthesia in patients with cancer disorders. Curr Opin Anaesthesiol. 2012 Jun;25(3):376-84.

Okła K, Rajtak A, Czerwonka A, Bobiński M, Wawruszak A, Tarkowski R, Bednarek W, Szumiło J, Kotarski J. Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1. J Transl Med. 2020 Jun 1;18(1):220. doi: 10.1186/s12967-020-02389-7. Erratum in: J Transl Med. 2020 Jun 25;18(1):258.

Sun J, Lu Q, Sanmamed MF, Wang J. Siglec-15 as an Emerging Target for Next-generation Cancer Immunotherapy. Clin Cancer Res. 2021 Feb 1;27(3):680-688. doi: 10.1158/1078-0432.CCR-19-2925. Epub 2020 Sep 21. Erratum in: Clin Cancer Res. 2021 Jul 1;27(13):3804.

Smolarz B, Biernacka K, Łukasiewicz H, Samulak D, Piekarska E, Romanowicz H, Makowska M. Ovarian Cancer-Epidemiology, Classification, Pathogenesis, Treatment, and Estrogen Receptors' Molecular Backgrounds. Int J Mol Sci. 2025 May 12;26(10):4611.

Barua A, Bahr JM. Ovarian Cancer: Applications of Chickens to Humans. Annu Rev Anim Biosci. 2022 Feb 15;10:241-257.

Walker M, Jacobson M, Sobel M. Management of ovarian cancer risk in women with BRCA1/2 pathogenic variants. CMAJ. 2019 Aug 12;191(32):E886-E893.

Cheng X, Yan C, Zhao J, Lu G. CD47 as a biomarker for ovarian cancer: prospects and challenges. Postgrad Med J. 2025 Nov 18;101(1202):1248-1252.

Dovnik A, Dovnik NF. Vitamin D and Ovarian Cancer: Systematic Review of the Literature with a Focus on Molecular Mechanisms. Cells. 2020 Feb 1;9(2):335.

Dovnik A, Dovnik NF. Vitamin D and Ovarian Cancer: Systematic Review of the Literature with a Focus on Molecular Mechanisms. Cells. 2020 Feb 1;9(2):335. doi: 10.3390/cells9020335. PMID: 32024052; PMCID: PMC7072673.

Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R; Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003 Sep 1;21(17):3194-200.

Bedia JS, Jacobs IJ, Ryan A, Gentry-Maharaj A, Burnell M, Singh N, Manchanda R, Kalsi JK, Dawnay A, Fallowfield L, McGuire AJ, Campbell S, Parmar MKB, Menon U, Skates SJ. Estimating the ovarian cancer CA-125 preclinical detectable phase, in-vivo tumour doubling time, and window for detection in early stage: an exploratory analysis of UKCTOCS. EBioMedicine. 2025 Feb;112:105554.

Wu X, Liu J, An R, Yin R, Zhang Y, Zhou H, He A, Wang L, Zhang J, Liu Z, Duan W, Zhu J, Lou G, Chen G, Cheng Y, Xue F, Nick S, Wang H, Li D. First-line bevacizumab plus chemotherapy in Chinese patients with stage III/IV epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer: a phase III randomized controlled trial. J Gynecol Oncol. 2024 Sep;35(5):e99.

Afenteva D, Yu R, Rajavuori A, Salvadores M, Launonen IM, Lavikka K, Zhang K, Pirttikoski A, Marchi G, Jamalzadeh S, Isoviita VM, Li Y, Micoli G, Erkan EP, Falco MM, Ungureanu D, Lahtinen A, Oikkonen J, Hietanen S, Vähärautio A, Sur I, Virtanen A, Färkkilä A, Hynninen J, Muranen TA, Taipale J, Hautaniemi S. Multi-omics analysis reveals the attenuation of the interferon pathway as a driver of chemo-refractory ovarian cancer. Cell Rep Med. 2025 Sep 16;6(9):102316.

Refbacks

  • There are currently no refbacks.